Axsome Resolves All SUNOSI Patent Litigation, Securing Exclusivity Until 2040
AXSM has more than doubled off its 52-week low of $96.09.
Summary
Axsome Therapeutics has settled all patent litigation for its drug SUNOSI, ensuring market exclusivity until at least March 2040 and removing a key legal overhang.
Key Events · Legal and Risk Events · AXSM
-
Patent Litigation Resolved
Axsome Therapeutics has settled all outstanding patent litigation related to its product SUNOSI (solriamfetol) with generic applicants.
-
Generic Entry Date Set
Generic versions of SUNOSI can be sold starting on or after March 1, 2040, or September 1, 2040, if pediatric exclusivity is granted.
-
Long-Term Exclusivity Secured
The settlement provides Axsome with market exclusivity for SUNOSI for at least another 14 years, protecting future revenue streams.
-
Regulatory Review
The settlement agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
Analysis · AXSM · Life Sciences
This settlement removes significant legal uncertainty surrounding Axsome's key product, SUNOSI. By granting generic entry no earlier than 2040, Axsome secures a long period of market exclusivity, protecting a substantial revenue stream and providing long-term clarity for investors. This de-risks a major product, especially as the stock is trading near its 52-week high.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AXSM was trading at $231.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4B. The 52-week trading range was $96.09 to $238.56. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.